Literature DB >> 20960108

Heparanase-1 and Cyclooxygenase-2: prognostic indicators of malignancy in pheochromocytomas.

Yu Zhu1, Hong-chao He, Fei Yuan, Jun Zhang, Wen-bin Rui, Ju-ping Zhao, Zhou-jun Shen, Guang Ning.   

Abstract

The objective of this article is to evaluate Heparanase-1 and Cyclooxygenase-2 as tissue-based markers of pheochromocytoma prognosis. Ninety-two sporadic pheochromocytoma patients with a minimum of 8-year follow-up post-diagnosis were enrolled. Slides of normal adrenal glands in nephrectomy specimens from 20 patients with benign renal tumors were as control. Heparanase-1 and Cyclooxygenase-2 expression as well as microvessel density were examined using immunohistochemistry in tissues from these patients. Positive staining for Heparanase-1 was observed in 23.68% of the benign and 77.78% of the malignant cases, whereas none of the normal adrenal controls showed positive staining. Similarly, Cyclooxygenase-2 staining was seen in 23.68% of the benign versus 83.33% of the malignant cases, and none of the normal controls appeared positive for Cyclooxygenase-2. Using both HPA-1 and Cox-2 combined, the positive predictive value of malignancy was significantly increased to 0.72, compared to about 0.45 by their own. Malignant cases showed higher microvessel density compared to benign tumors and normal controls (36.41, 21.43, and 13.36%, respectively). Heparanase-1 and Cyclooxygenase-2 may contribute to the invasive characteristics of malignant pheochromocytomas. Heparanase-1 and Cyclooxygenase-2 combined is better than their own to be used as a marker to distinguish malignant from benign pheochromocytoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20960108     DOI: 10.1007/s12020-010-9356-y

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  24 in total

Review 1.  Pheochromocytoma.

Authors:  H C Klingler; P J Klingler; J K Martin; R C Smallridge; S L Smith; R A Hinder
Journal:  Urology       Date:  2001-06       Impact factor: 2.649

2.  COX-2 induction by heparanase in the progression of breast cancer.

Authors:  Takako Imada; Junji Matsuoka; Tetsuji Nobuhisa; Takaomi Okawa; Toshihiro Murata; Yoko Tabuchi; Yasuhiro Shirakawa; Nobuya Ohara; Mehmet Gunduz; Hitoshi Nagatsuka; Tatsuo Umeoka; Yasuhisa Yamamoto; Motowo Nakajima; Noriaki Tanaka; Yoshio Naomoto
Journal:  Int J Mol Med       Date:  2006-02       Impact factor: 4.101

3.  Heparanase is involved in angiogenesis in esophageal cancer through induction of cyclooxygenase-2.

Authors:  Takaomi Okawa; Yoshio Naomoto; Tetsuji Nobuhisa; Munenori Takaoka; Takayuki Motoki; Yasuhiro Shirakawa; Tomoki Yamatsuji; Hiroyasu Inoue; Mamoru Ouchida; Mehmet Gunduz; Motowo Nakajima; Noriaki Tanaka
Journal:  Clin Cancer Res       Date:  2005-11-15       Impact factor: 12.531

4.  The close relationship between heparanase and cyclooxygenase-2 expressions in signet-ring cell carcinoma of the stomach.

Authors:  Yasuyuki Ohtawa; Yoshio Naomoto; Yasuhiro Shirakawa; Munenori Takaoka; Toshihiro Murata; Ryotaro Sonoda; Kazufumi Sakurama; Tomoki Yamatsuji; Mehmet Gunduz; Hidetsugu Tsujigiwa; Hitoshi Nagatsuka; Norihiko Terada; Satoshi Itano; Sadayuki Horiki; Kazuyoshi Yanagihara; Motowo Nakajima; Noriaki Tanaka
Journal:  Hum Pathol       Date:  2006-07-07       Impact factor: 3.466

5.  Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis.

Authors:  M D Hulett; C Freeman; B J Hamdorf; R T Baker; M J Harris; C R Parish
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

6.  Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma.

Authors:  S Gupta; M Srivastava; N Ahmad; D G Bostwick; H Mukhtar
Journal:  Prostate       Date:  2000-01       Impact factor: 4.104

7.  Angiogenic Index: A New Method for Assessing Microvascularity in Breast Carcinoma with Possible Prognostic Implications.

Authors:  Juan B. M. Laforga; F. Ignacio Aranda
Journal:  Breast J       Date:  2000-03       Impact factor: 2.431

8.  Increased expression of cyclooxygenase-2 in malignant pheochromocytomas.

Authors:  K Salmenkivi; C Haglund; A Ristimäki; J Arola; P Heikkilä
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

Review 9.  Malignant pheochromocytoma: current status and initiatives for future progress.

Authors:  Graeme Eisenhofer; Stefan R Bornstein; Frederieke M Brouwers; Nai-Kong V Cheung; Patricia L Dahia; Ronald R de Krijger; Thomas J Giordano; Lloyd A Greene; David S Goldstein; Hendrik Lehnert; William M Manger; John M Maris; Hartmut P H Neumann; Karel Pacak; Barry L Shulkin; David I Smith; Arthur S Tischler; William F Young
Journal:  Endocr Relat Cancer       Date:  2004-09       Impact factor: 5.678

10.  Higher gastric cycloxygenase-2 expression and precancerous change in Helicobacter pylori-infected relatives of gastric cancer patients.

Authors:  Bor-Shyang Sheu; Hsiao-Bai Yang; Shew-Meei Sheu; Ay-Huey Huang; Jiunn-Jong Wu
Journal:  Clin Cancer Res       Date:  2003-11-01       Impact factor: 12.531

View more
  6 in total

1.  Expression of STAT3 and IGF2 in adrenocortical carcinoma and its relationship with angiogenesis.

Authors:  Y Zhu; Y Xu; D Chen; C Zhang; W Rui; J Zhao; Q Zhu; Y Wu; Z Shen; W Wang; G Ning; X Wang
Journal:  Clin Transl Oncol       Date:  2013-11-01       Impact factor: 3.405

2.  Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy.

Authors:  Yun-Ze Xu; Yu Zhu; Zhou-Jun Shen; Jia-Yan Sheng; Hong-Chao He; Gui Ma; Yi-Cheng Qi; Ju-Ping Zhao; Yu-Xuan Wu; Wen-Bin Rui; Qing Wei; Wen-Long Zhou; Xin Xie; Guang Ning
Journal:  Endocrine       Date:  2011-06-25       Impact factor: 3.633

Review 3.  Pheochromocytomas and paragangliomas: assessment of malignant potential.

Authors:  Tim I M Korevaar; Ashley B Grossman
Journal:  Endocrine       Date:  2011-10-25       Impact factor: 3.633

4.  Effect of HSP90 inhibitor in pheochromocytoma PC12 cells: an experimental investigation.

Authors:  Yunze Xu; Chongyu Zhang; Dongning Chen; Juping Zhao; Zhoujun Shen; Yuxuan Wu; Yu Zhu
Journal:  Tumour Biol       Date:  2013-07-20

5.  Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.

Authors:  Lieyu Xu; Yicheng Qi; Yunze Xu; Jianpo Lian; Xiaojing Wang; Guang Ning; Weiqing Wang; Yu Zhu
Journal:  Oncotarget       Date:  2016-06-14

Review 6.  Imaging pheochromocytoma in small animals: preclinical models to improve diagnosis and treatment.

Authors:  Hermine Mohr; Alessia Foscarini; Katja Steiger; Simone Ballke; Christoph Rischpler; Franz Schilling; Natalia S Pellegata
Journal:  EJNMMI Res       Date:  2021-12-11       Impact factor: 3.434

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.